Cite
HARVARD Citation
Mease, P. et al. (2021). Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Annals of the rheumatic diseases. 80 (9), pp. 1147-1157. [Online].